Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | ICMT | O60725 | 9/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9235686 | 0.84 | ICMT (0.57) | ERBB2HTR2AHTR2CNTSR1ICMT | |
| SCHEMBL25010274 | 0.84 | HTR2A (0.55) | HTR2AHTR2CKDM4EMAPTEGFR | |
| Methylamine SCHEMBL27990030 | 0.82 | ICMT (0.56) | ERBB2HTR2AHTR2CNTSR1ICMT | |
| SCHEMBL9234984 | 0.78 | ICMT (0.59) | ICMT | |
| SCHEMBL12879254 | 0.74 | HTR2C (0.55) | HTR2AHTR2CKDM4EMAPTNPSR1 | |
| SCHEMBL11961043 | 0.74 | HSD11B1 (0.63) | NR3C1HSD11B1 | |
| SCHEMBL4022763 | 0.73 | SERPINE1 (0.57) | ERBB2ICMTHDAC8HDAC6 | |
| SCHEMBL6100410 | 0.72 | HTR2C (0.57) | HTR2AHTR2CKDM4EMAPTHDAC8 | |
| SCHEMBL9092842 | 0.71 | HTR2A (0.54) | HTR2AHTR2CNTSR1EGFR | |
| SCHEMBL30267597 | 0.71 | HTR2C (0.54) | HTR2AHTR2CEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742100-B2 | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-06-03 | — | — | US | disclosed |
| US-20120197014-A1 | SMALL MOLECULE INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE WITH POTENTIAL ANTICANCER ACTIVITY | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197014-A1 | SMALL MOLECULE INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE WITH POTENTIAL ANTICANCER ACTIVITY | ICMT, BHMT, SHMT1 | ERBB2 3560/4885HTR2A 4607/4885HTR2C 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.